To determine the efficacy and safety of daily doses of IV micafungin versus IV caspofungin for the treatment of esophageal candidiasis

Inclusion Criteria:

• Esophageal candidiasis confirmed by endoscopy
• Negative pregnancy test for female patients of childbearing potential

Exclusion Criteria:

• Pregnant or nursing female patient
• Evidence of liver disease
• Another active opportunistic fungal infection and/or receiving acute systemic therapy for an opportunistic fungal infection
• Concomitant esophagitis caused by herpes simplex virus or cytomegalovirus
• Received an oral or topical antifungal agent within 48 hours or a systemic antifungal agent within 72 hours of first dose of study drug
• Known to be non-responsive to therapy in any prior systemic antifungal clinical trail
• Experienced > 2 episodes of esophageal candidiasis requiring systemic antifungal therapy
• History of anaphylaxis attributed to echinocandin class of antifungals